Study of p53, c-erbB-2, and EGFr in Bladder Cancer
Author Information
Author(s): C. Wright, K. Mellon, P. Johnston, D.P. Lane, A.L. Harris, C.H.W. Horne, D.E. Neal
Primary Institution: University Department of Pathology and Surgery/Urology, Newcastle-upon-Tyne
Hypothesis
The expression of p53, c-erbB-2, and EGFr proteins may have clinical significance in transitional cell carcinoma of the bladder.
Conclusion
Alterations in the expression of p53, c-erbB-1, and c-erbB-2 are common in bladder cancer and may help define patient sub-groups with different prognoses.
Supporting Evidence
- 54% of tumors stained positively for p53.
- 15% of tumors showed strong staining for c-erbB-2.
- 31% of tumors were positive for EGFr.
- 85% of muscle invasive tumors were stained positively for either p53 or EGFr.
Takeaway
The study looked at proteins related to bladder cancer in 82 patients, finding that many had changes in these proteins that could help doctors understand their cancer better.
Methodology
Immuno-histochemical methods were used to study protein expression in tumor samples from patients.
Limitations
Some tumors did not have enough tissue for staining, and the study may not detect all mutations in p53.
Participant Demographics
56 males and 26 females, mean age 69 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website